Navigation Links
Sanofi-aventis enters into a research and development collaboration with UCSF
Date:1/12/2011

Paris, France - January 12, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the University of California, San Francisco (UCSF) have formed two research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first is an oncology partnership that will focus on project-based collaboration to accelerate research progress through the clinical proof of concept stage. The second collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation.

Sanofi-aventis will be the first industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR). The PBBR program awards funding to projects of potentially high impact and greater creativity, which offer an innovative approach to scientific discovery. The partnership with UCSF enhances sanofi-aventis' approach of setting up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.

Under the terms of the agreement, a UCSF/sanofi-aventis Joint Steering Committee will choose from among UCSF-generated proposals identified for their scientific excellence. Sanofi-aventis will fund up to five grants a year, making additional funds available for student or fellow interns at sanofi-aventis to conduct collaborative research. To further this exchange of ideas, sanofi-aventis will fund an annual research forum bringing together sanofi-aventis and UCSF researchers to share knowledge and perspectives on relevant scientific matters and to review progress of research projects funded through the collaboration.

"As the largest public biomedical research institution in America, UCSF is dedicated to accelerating the translation of leading-edge research into state-of-the-art care for patients," said UCSF Chancellor Susan Desmond-Hellmann, MD, MPH. "This collaboration will help support ground-breaking projects that could offer the greatest possibilities in each of these fields."

"Joining forces with UCSF researchers emphasizes sanofi-aventis' commitment to establish strong relationships and collaborations with the best innovators in the world," said Christopher A. Viehbacher, Chief Executive Officer, sanofi-aventis. "By promoting open and deep scientific exchange between UCSF's leading researchers and sanofi-aventis' drug development experts, we aim to generate significant healthcare advances in multiple therapeutic areas, to discover and develop comprehensive healthcare solutions for patients."


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related biology news :

1. Dana-Farber and sanofi-aventis establish cancer research alliance
2. NINDS awards new Udall Centers for Parkinsons Disease Research
3. Blood-thinning copycat enters malaria fight
4. DFG approves 12 new collaborative research centers
5. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
6. Oxford University Press enters publishing partnership with Infectious Diseases Society of America
7. DFG approves funding for 17 new collaborative research centers
8. Graffinity Enters into Drug Discovery Research Collaboration with Genentech
9. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
10. BIO-key(R) Enters Strategic Partnership With Nlets
11. BIO-key(R) Enters Strategic Partnership With Nlets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology: